A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy

Niranjan Manoharan; Prem Sagar Subramanian

doi:10.1016/j.ajoc.2017.03.002

A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy

Am J Ophthalmol Case Rep. 2017 Mar 8:6:55-57. doi: 10.1016/j.ajoc.2017.03.002. eCollection 2017 Jun.

Authors

Niranjan Manoharan¹, Prem Sagar Subramanian^{1

2

3}

Affiliations

¹ Departments of Ophthalmology, University of Colorado School of Medicine, Aurora, CO, USA.
² Departments of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
³ Departments of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA.

Abstract

Purpose: To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C.

Observations: We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient.

Conclusions and importance: NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.

Keywords: Harvoni; Ischemic optic neuropathy; NAION.

Publication types

Case Reports